Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC
Turning Point Therapeutics, Inc.
This trial has two experimental phases. Phase 1 is assessing the safety, tolerability, PK, MTD, and RP2D of TPX-0131. Phase 2 will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts. Participants will receive TPX-0131 via oral tablets.